PT2940014T - Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo - Google Patents

Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo

Info

Publication number
PT2940014T
PT2940014T PT13867650T PT13867650T PT2940014T PT 2940014 T PT2940014 T PT 2940014T PT 13867650 T PT13867650 T PT 13867650T PT 13867650 T PT13867650 T PT 13867650T PT 2940014 T PT2940014 T PT 2940014T
Authority
PT
Portugal
Prior art keywords
suppressant
isoindole
dihydro
derivative
pharmaceutical composition
Prior art date
Application number
PT13867650T
Other languages
English (en)
Portuguese (pt)
Inventor
Rae Hong Yong
eun na Jeong
Sook Min Im
Ju Cha Hyun
Ki Kwon Sool
Ro Seonggu
Myung Cho Joong
Original Assignee
Crystalgenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics Inc filed Critical Crystalgenomics Inc
Publication of PT2940014T publication Critical patent/PT2940014T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT13867650T 2012-12-28 2013-12-26 Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo PT2940014T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28

Publications (1)

Publication Number Publication Date
PT2940014T true PT2940014T (pt) 2018-11-28

Family

ID=51021712

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13867650T PT2940014T (pt) 2012-12-28 2013-12-26 Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo

Country Status (15)

Country Link
US (4) US9758508B2 (enExample)
EP (2) EP3428161B1 (enExample)
JP (2) JP6325573B2 (enExample)
KR (1) KR102009163B1 (enExample)
CN (1) CN104995184B (enExample)
AU (3) AU2013371146C1 (enExample)
BR (1) BR112015015477B1 (enExample)
CA (1) CA2896711C (enExample)
DK (1) DK2940014T3 (enExample)
ES (2) ES2929906T3 (enExample)
MX (2) MX386542B (enExample)
PL (1) PL2940014T3 (enExample)
PT (1) PT2940014T (enExample)
RU (2) RU2018138028A (enExample)
WO (1) WO2014104757A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
CA2896711C (en) * 2012-12-28 2019-12-31 Crystalgenomics, Inc. 2,3-dihydro-isoindol-1-one derivatives and methods of use thereof as btk inhibitor
ES2857081T3 (es) 2015-07-16 2021-09-28 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
US20180344702A1 (en) * 2017-02-21 2018-12-06 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3886840A4 (en) * 2018-11-30 2022-08-24 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4274567A1 (en) * 2021-01-05 2023-11-15 Sumitomo Pharma Oncology, Inc. Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor
JP2024509192A (ja) * 2021-03-05 2024-02-29 ニンバス サターン, インコーポレイテッド Hpk1アンタゴニスト及びその使用
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60205100T2 (de) * 2001-04-12 2006-06-01 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
JP2006526648A (ja) * 2003-06-02 2006-11-24 アボット・ラボラトリーズ キナーゼ阻害剤としてのイソインドリン−1−オン化合物
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2006112479A1 (ja) 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
CA2645583A1 (en) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
JPWO2008047831A1 (ja) * 2006-10-17 2010-02-25 協和発酵キリン株式会社 Jak阻害剤
CA2701275C (en) 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
CA2896711C (en) * 2012-12-28 2019-12-31 Crystalgenomics, Inc. 2,3-dihydro-isoindol-1-one derivatives and methods of use thereof as btk inhibitor
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Also Published As

Publication number Publication date
KR20160058720A (ko) 2016-05-25
MX2015008396A (es) 2016-04-15
AU2020201431A1 (en) 2020-03-19
WO2014104757A1 (ko) 2014-07-03
JP2016504351A (ja) 2016-02-12
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
AU2013371146A1 (en) 2015-07-16
JP6596537B2 (ja) 2019-10-23
CA2896711A1 (en) 2014-07-03
MX2021011563A (es) 2022-10-10
EP2940014A1 (en) 2015-11-04
AU2013371146C1 (en) 2019-01-17
US20150336934A1 (en) 2015-11-26
AU2018214134B2 (en) 2020-03-12
CN104995184A (zh) 2015-10-21
EP3428161A1 (en) 2019-01-16
EP3428161B1 (en) 2022-09-07
HK1259355A1 (en) 2019-11-29
RU2015124381A (ru) 2017-02-01
MX386542B (es) 2025-03-18
US9758508B2 (en) 2017-09-12
PL2940014T3 (pl) 2019-03-29
RU2018138028A (ru) 2019-03-21
US20220380346A1 (en) 2022-12-01
DK2940014T3 (en) 2018-12-10
ES2929906T3 (es) 2022-12-02
CA2896711C (en) 2019-12-31
US20170362205A1 (en) 2017-12-21
EP2940014B1 (en) 2018-09-26
JP6325573B2 (ja) 2018-05-16
RU2671847C2 (ru) 2018-11-07
AU2020201431B2 (en) 2021-07-22
AU2013371146B2 (en) 2018-05-10
US11230539B2 (en) 2022-01-25
ES2696700T3 (es) 2019-01-17
US20210009565A1 (en) 2021-01-14
EP2940014A4 (en) 2016-06-22
KR102009163B1 (ko) 2019-08-09
US10604508B2 (en) 2020-03-31
JP2018109069A (ja) 2018-07-12
CN104995184B (zh) 2018-01-02
AU2018214134A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
PL2940014T3 (pl) Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna
ZA201406233B (en) Pharmaceutical composition and administration thereof
IL237839A0 (en) History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
IL237072B (en) History of isoquinolinone, their preparation and pharmaceutical preparations containing them
IL235414A (en) The history of pyrolotriazinone, their preparation and their pharmaceutical preparations
IL237073A (en) History of pyridopyrimidine, their preparation and their pharmaceutical preparations
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
IL238825B (en) The history of heterocyclics, their preparation and pharmaceutical preparations containing them
ZA201505318B (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
IL233602A (en) The history of benzamide, their preparation and their pharmaceutical preparations
IL233529A (en) 1, 5-Naphthyridine derivatives and lactose-containing pharmacological preparations
IL232577A0 (en) The history of morpholinylbenzotriazine, their preparation and pharmaceutical preparations containing them
SG11201509436TA (en) Pharmaceutical composition, preparation and uses thereof
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
IL239054B (en) History of azaquinazoline carboxamide, their preparation and pharmaceutical preparations containing them
IL235955A0 (en) The history of benzothiophene, their preparation and pharmaceutical preparations containing them
IL246298A0 (en) History of piperidine, their preparation and pharmaceutical preparations containing them
IL231699A (en) History of benzyl piperidine, their preparation and their pharmaceutical preparations